Dr. Murali Ramachandra is the CEO of Aurigene Oncology Limited, a subsidiary of Dr. Reddy’s Laboratories focused on the discovery and development of innovative therapeutics. Prior to his current role, Dr. Ramachandra served as the CSO at Aurigene. He received his PhD from the University of Idaho (USA) and completed post-doctoral training at DuPont and the University of Kansas Medical Center (USA). With notable roles at the National Cancer Institute (NIH, USA) and Schering Plough Research Institute (USA, now Merck), Dr. Ramachandra has worked on various aspects of cancer biology and drug discovery. He has contributed to the discovery and development of 19 clinical-stage innovative therapeutics and the first globally approved adenoviral gene therapy product for cancer, ADSTILADRIN for bladder cancer. With over 25 years of research experience, he has co-authored more than 75 scientific publications and holds 30 granted international patents